The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
- 29 June 2020
- journal article
- review article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 26 (6), 562-586
- https://doi.org/10.1017/s1092852920001546
Abstract
This is a report of a joint World Psychiatric Association/International College of Neuropsychopharmacology (WPA/CINP) workgroup concerning the risk/benefit ratio of antipsychotics in the treatment of schizophrenia. It utilized a selective but, within topic, comprehensive review of the literature, taking into consideration all the recently discussed arguments on the matter and avoiding taking sides when the results in the literature were equivocal. The workgroup's conclusions suggested that antipsychotics are efficacious both during the acute and the maintenance phase, and that the current data do not support the existence of a supersensitivity rebound psychosis. Long-term treated patients have better overall outcome and lower mortality than those not taking antipsychotics. Longer duration of untreated psychosis and relapses are modestly related to worse outcome. Loss of brain volume is evident already at first episode and concerns loss of neuropil volume rather than cell loss. Progression of volume loss probably happens in a subgroup of patients with worse prognosis. In humans, antipsychotic treatment neither causes nor worsens volume loss, while there are some data in favor for a protective effect. Schizophrenia manifests 2 to 3 times higher mortality vs the general population, and treatment with antipsychotics includes a number of dangers, including tardive dyskinesia and metabolic syndrome; however, antipsychotic treatment is related to lower mortality, including cardiovascular mortality. In conclusion, the literature strongly supports the use of antipsychotics both during the acute and the maintenance phase without suggesting that it is wise to discontinue antipsychotics after a certain period of time. Antipsychotic treatment improves long-term outcomes and lowers overall and specific-cause mortality.Keywords
This publication has 218 references indexed in Scilit:
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisInternational Journal of Neuropsychopharmacology, 2013
- The Myth of Schizophrenia as a Progressive Brain DiseaseSchizophrenia Bulletin, 2012
- Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studiesTranslational Psychiatry, 2012
- Long-term Antipsychotic Treatment and Brain VolumesArchives of General Psychiatry, 2011
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Clinical Course and Outcome of Schizophrenia in a Predominantly Treatment-Naive Cohort in Rural EthiopiaSchizophrenia Bulletin, 2009
- A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With SchizophreniaSchizophrenia Bulletin, 2007
- Methodological Issues in Current Antipsychotic Drug TrialsSchizophrenia Bulletin, 2007
- Schizophrenia in Translation: Is Active Psychosis Neurotoxic?Schizophrenia Bulletin, 2005